Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:comparator |
placebo
|
| gptkbp:completedIn |
2020
|
| gptkbp:controls |
placebo
|
| gptkbp:endPoint |
change in HbA1c
|
| gptkbp:enrollment |
478
|
| gptkbp:focusesOn |
gptkb:type_2_diabetes
|
| https://www.w3.org/2000/01/rdf-schema#label |
SURPASS-1
|
| gptkbp:intervention |
tirzepatide 10 mg
tirzepatide 15 mg tirzepatide 5 mg |
| gptkbp:location |
multinational
|
| gptkbp:number |
NCT03954834
|
| gptkbp:period |
Phase 3
|
| gptkbp:population |
adults with type 2 diabetes inadequately controlled with diet and exercise
|
| gptkbp:result |
tirzepatide significantly reduced HbA1c compared to placebo
tirzepatide significantly reduced body weight compared to placebo |
| gptkbp:resultPublication |
The Lancet, 2021
|
| gptkbp:safetyOutcome |
gastrointestinal adverse events most common
|
| gptkbp:secondaryEndpoint |
change in body weight
|
| gptkbp:sponsor |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:startDate |
2018
|
| gptkbp:studies |
gptkb:tirzepatide
|
| gptkbp:bfsParent |
gptkb:tirzepatide
|
| gptkbp:bfsLayer |
7
|